Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7 MULTIVARIATE MODELLING
2.8 PRODUCT TYPE LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
5 PATENT ANALYSIS OF NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET
5.1 DBMR ANALYSIS
5.2 COUNTRY-LEVEL ANALYSIS
5.3 YEARWISE ANALYSIS
6 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET: PIPELINE ANALYSIS
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 INCREASE IN DEMAND FOR BLOOD TRANSFUSION
7.1.2 INCREASED FUNDING FOR PRODUCT DEVELOPMENT
7.1.3 RISE IN BLOOD-RELATED DISORDERS AND TRAUMA CASES
7.1.4 LIMITED AVAILABILITY OF FRESH BLOOD AND SMALL STORAGE PERIODS OF FRESH BLOOD
7.2 RESTRAINTS
7.2.1 STRINGENT REGULATORY APPROVAL PROCESS
7.2.2 HIGH-COST PRODUCTION OF ARTIFICIAL BLOOD SUBSTITUTE
7.2.3 UNAWARENESS ABOUT THE ARTIFICIAL BLOOD SUBSTITUTES
7.3 OPPORTUNITIES
7.3.1 INCREASE IN AWARENESS REGARDING THE ADVANTAGES OF ARTIFICIAL BLOOD OVER HUMAN BLOOD
7.3.2 RISE IN DEMAND FOR BLOOD SUBSTITUTES AND INSUFFICIENT NUMBER OF BLOOD DONORS
7.3.3 RISE IN NUMBER OF RESEARCH & DEVELOPMENTS ON ARTIFICIAL BLOOD
7.3.4 AMPLE AMOUNT OF SOURCES FOR PRODUCTION OF ARTIFICIAL BLOOD SUBSTITUTE
7.4 CHALLENGES
7.4.1 INSTABILITY OF ARTIFICIAL BLOOD PRODUCT
7.4.2 EXTENDED CLINICAL TRAILS
7.4.3 SIDE EFFECTS OF ARTIFICIAL BLOOD SUBSTITUTES
8 IMPACT OF COVID-19 ON THE NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET
8.1 AFTERMATH OF COVID-19
8.2 IMPACT ON SUPPLY AND DEMAND
8.3 THE INCREASING DEMAND FOR BLOOD TRANSFUSION IS LEADING THE ARTIFICIAL BLOOD SUBSTITUTES MARKET.
8.4 CONCLUSION
9 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY PRODUCT TYPE
9.1 OVERVIEW
9.2 HEMOGLOBIN-BASED OXYGEN CARRIES (HBOCS)
9.2.1 OXYGLOBIN
9.2.2 HEMOPURE
9.3 PERFLUOROCARBON (PFCS)
9.3.1 PERFTORAN
9.3.2 OTHERS
10 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY SOURCE
10.1 OVERVIEW
10.2 ANIMAL BLOOD
10.3 HUMAN BLOOD
10.4 MICROORGANISM BASED RECOMBINANT HB
10.5 STEM CELLS
10.6 SYNTHETIC POLYMERS
11 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY APPLICATION
11.1 OVERVIEW
11.2 INJURIES
11.3 CARDIOVASCULAR DISEASES
11.4 ORGAN TRANSPLANT
11.5 MATERNAL CONDITION
11.6 MALIGNANT NEOPLASMA
11.7 NEONATAL CONDITIONS
12 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY END USER
12.1 OVERVIEW
12.2 HOSPITAL AND CLINICS
12.3 BLOOD BANKS
12.4 OTHERS
13 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY REGION
13.1 NORTH AMERICA
13.1.1 U.S.
13.1.2 MEXICO
14 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET: COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
15 SWOT
16 COMPANY PROFILE
16.1 KALOCYTE, INC.
16.1.1 COMPANY SNAPSHOT
16.1.2 COMPANY SAHRE ANALYSIS
16.1.3 PRODUCT PORTFOLIO
16.1.4 RECENT DEVELOPMENTS
16.2 HEMARINA
16.2.1 COMPANY SNAPSHOT
16.2.2 COMPANY SHARE ANALYSIS
16.2.3 PRODUCT PORTFOLIO
16.2.4 RECENT DEVELOPMENTS
16.3 HEMOGLOBIN OXYGEN THERAPEUTICS LLC
16.3.1 COMPANY SNAPSHOT
16.3.2 COMPANY SHARE ANALYSIS
16.3.3 PRODUCT PORTFOLIO
16.3.4 RECENT DEVELOPMENTS
16.4 LLC “VISUSMED”
16.4.1 COMPANY SNAPSHOT
16.4.2 COMPANY SHARE ANALYSIS
16.4.3 PRODUCT PORTFOLIO
16.4.4 RECENT DEVELOPMENT
16.5 EUROPEAN MEDICINES AGENCY
16.5.1 COMPANY SNAPSHOT
16.5.2 REVENUE ANALYSIS
16.5.3 COMPANY SHARE ANALYSIS
16.5.4 PRODUCT PORTFOLIO
16.5.5 RECENT DEVELOPMENT
16.6 AURUM BIOSCIENCES
16.6.1 COMPANY SNAPSHOT
16.6.2 PRODUCT PORTFOLIO
16.6.3 RECENT DEVELOPMENTS
16.7 BOSTON THERAPEUTICS, INC.
16.7.1 COMPANY SNAPSHOT
16.7.2 REVENUE ANALYSIS
16.7.3 PRODUCT PORTFOLIO
16.7.4 RECENT DEVELOPMENT
16.8 NANOBLOOD LLC
16.8.1 COMPANY SNAPSHOT
16.8.2 PRODUCT PORTFOLIO
16.8.3 RECENT DEVELOPMENT
16.9 NUVOX PHARMA
16.9.1 COMPANY SNAPSHOT
16.9.2 PRODUCT PORTFOLIO
16.9.3 RECENT DEVELOPMENTS
16.1 OPK BIOTECH LLC
16.10.1 COMPANY SNAPSHOT
16.10.2 PRODUCT PORTFOLIO
16.10.3 RECENT DEVELOPMENT
16.11 OXYVITA INC
16.11.1 COMPANY SNAPSHOT
16.11.2 PRODUCT PORTFOLIO
16.11.3 RECENT DEVELOPMENT
16.12 PROLONG PHARMACEUTICALS, LLC
16.12.1 COMPANY SNAPSHOT
16.12.2 PRODUCT PORTFOLIO
16.12.3 RECENT DEVELOPMENT
17 QUESTIONNAIRE
18 RELATED REPORTS
List of Table
TABLE 1 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET, PRODUCT TYPE, 2019-2028 (USD THOUSAND)
TABLE 2 NORTH AMERICA HEMOGLOBIN-BASED OXYGEN CARRIES (HBOCS) IN ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 3 NORTH AMERICA HEMOGLOBIN-BASED OXYGEN CARRIERS (HBOCS) IN ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY PRODUCT TYPE, 2019-2028 (USD THOUSAND)
TABLE 4 NORTH AMERICA PERFLUOROCARBON (PFCS) IN ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 5 NORTH AMERICA PERFLUOROCARBON (PFCS) IN ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY PRODUCT TYPE, 2019-2028 (USD THOUSAND)
TABLE 6 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY SOURCE, 2019-2028 (USD THOUSAND)
TABLE 7 NORTH AMERICA ANIMAL BLOOD IN ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 8 NORTH AMERICA HUMAN BLOOD IN ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 9 NORTH AMERICA MICROORGANISM BASED RECOMBINANT HB IN ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 10 NORTH AMERICA STEM CELLS IN ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 11 NORTH AMERICA SYNTHETIC POLYMERS IN ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 12 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY APPLICATION, 2019-2028 (USD THOUSAND)
TABLE 13 NORTH AMERICA INJURIES IN ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 14 NORTH AMERICA CARDIOVASCULAR DISEASES IN ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 15 NORTH AMERICA ORGAN TRANSPLANT IN ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 16 NORTH AMERICA MATERNAL CONDITION IN ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 17 NORTH AMERICA MALIGNANT NEOPLASMA IN ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 18 NORTH AMERICA NEONATAL CONDITIONS IN ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 19 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY END USER, 2019-2028 (USD THOUSAND)
TABLE 20 NORTH AMERICA HOSPITALS AND CLINICS IN ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 21 NORTH AMERICA BLOOD BANKS IN ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 22 NORTH AMERICA OTHERS IN ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 23 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY COUNTRY, 2019-2028 (USD THOUSAND)
TABLE 24 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY PRODUCT TYPE, 2019-2028 (USD THOUSAND)
TABLE 25 NORTH AMERICA HEMOGLOBIN-BASED OXYGEN CARRIES (HBOCS) IN ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY PRODUCT TYPE, 2019-2028 (USD THOUSAND)
TABLE 26 NORTH AMERICA PERFLUOROCARBON (PFCS) IN ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY PRODUCT TYPE, 2019-2028 (USD THOUSAND)
TABLE 27 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY SOURCE, 2019-2028 (USD THOUSAND)
TABLE 28 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY APPLICATION, 2019-2028 (USD THOUSAND)
TABLE 29 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY END USER, 2019-2028 (USD THOUSAND)
TABLE 30 U.S. ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY PRODUCT TYPE, 2019-2028 (USD THOUSAND)
TABLE 31 U.S. HEMOGLOBIN-BASED OXYGEN CARRIES (HBOCS) IN ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY PRODUCT TYPE, 2019-2028 (USD THOUSAND)
TABLE 32 U.S. PERFLUOROCARBON (PFCS) IN ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY PRODUCT TYPE, 2019-2028 (USD THOUSAND)
TABLE 33 U.S. ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY SOURCE, 2019-2028 (USD THOUSAND)
TABLE 34 U.S. ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY APPLICATION, 2019-2028 (USD THOUSAND)
TABLE 35 U.S. ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY END USER, 2019-2028 (USD THOUSAND)
TABLE 36 MEXICO ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY PRODUCT TYPE, 2019-2028 (USD THOUSAND)
TABLE 37 MEXICO HEMOGLOBIN-BASED OXYGEN CARRIES (HBOCS) IN ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY PRODUCT TYPE, 2019-2028 (USD THOUSAND)
TABLE 38 MEXICO PERFLUOROCARBON (PFCS) IN ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY PRODUCT TYPE, 2019-2028 (USD THOUSAND)
TABLE 39 MEXICO ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY SOURCE, 2019-2028 (USD THOUSAND)
TABLE 40 MEXICO ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY APPLICATION, 2019-2028 (USD THOUSAND)
TABLE 41 MEXICO ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY END USER, 2019-2028 (USD THOUSAND)
List of Figure
FIGURE 1 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET: DBMR MARKET POSITION GRID
FIGURE 8 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 9 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET: DBMR VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET: SEGMENTATION
FIGURE 11 INCREASED DEMAND FOR BLOOD TRANSFUSION IS EXPECTED TO DRIVE THE NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 12 HAEMOGLOBIN-BASED OXYGEN CARRIERS (HBOCS) SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET IN 2021 & 2028
FIGURE 13 PATENT REGISTERED FOR ARTIFICIAL BLOOD SUBSTITUTES, BY COUNTRY
FIGURE 14 PATENT REGISTERED YEAR (2017 - 2021)
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET
FIGURE 16 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY PRODUCT TYPE, 2020
FIGURE 17 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY SOURCE, 2020
FIGURE 18 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY APPLICATION, 2020
FIGURE 19 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY END USER, 2020
FIGURE 20 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET: SNAPSHOT (2020)
FIGURE 21 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET: BY COUNTRY (2020)
FIGURE 22 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET: BY COUNTRY (2021 & 2028)
FIGURE 23 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET: BY COUNTRY (2020 & 2028)
FIGURE 24 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET: BY PRODUCT TYPE (2021-2028)
FIGURE 25 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET: COMPANY SHARE 2020 (%)
